[HTML][HTML] Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the …
JMS Bartlett, CL Brookes, T Robson… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
JMS Bartlett, CL Brookes, T Robson, CJH van de Velde, LJ Billingham, FM Campbell…
Journal of clinical oncology, 2011•ncbi.nlm.nih.govPurpose The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial included a
prospectively planned pathology substudy testing the predictive value of progesterone
receptor (PgR) expression for outcome of estrogen receptor–positive (ER-positive) early
breast cancer treated with exemestane versus tamoxifen.
prospectively planned pathology substudy testing the predictive value of progesterone
receptor (PgR) expression for outcome of estrogen receptor–positive (ER-positive) early
breast cancer treated with exemestane versus tamoxifen.
Abstract
Purpose
The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial included a prospectively planned pathology substudy testing the predictive value of progesterone receptor (PgR) expression for outcome of estrogen receptor–positive (ER-positive) early breast cancer treated with exemestane versus tamoxifen.
ncbi.nlm.nih.gov